Ausgabe 5/2021
Inhalt (6 Artikel)
Cardiometabolic Disease and Treatment (E. Brinton, Section Editor)
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Ioannis Akoumianakis, Evangelia Zvintzou, Kyriakos Kypreos, Theodosios D. Filippatos
Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)
Polypills in Cardiovascular Disease Prevention: Mass-Strategy Approach, Precision Medicine, or an Essential Intertwine Between Them?
Giuliano Generoso, Marcio Sommer Bittencourt
Evidence-Based Medicine, Clinical Trials and Their Interpretations (K. Nasir, Section Editor)
Strengthening the Learning Health System in Cardiovascular Disease Prevention: Time to Leverage Big Data and Digital Solutions
Anjali A Wagle, Nino Isakadze, Khurram Nasir, Seth Shay Martin
Open Access
Statin Drugs (R. Ceska, Section Editor)
Lipid Lowering Drugs: Present Status and Future Developments
Massimiliano Ruscica, Nicola Ferri, Raul D. Santos, Cesare R. Sirtori, Alberto Corsini
Nutrition (K. Petersen, Section Editor)
Time-Restricted Eating to Improve Cardiovascular Health
Kelsey Gabel, Sofia Cienfuegos, Faiza Kalam, Mark Ezpeleta, Krista A. Varady
Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors)
Breast Arterial Calcification: A Potential Biomarker for Atherosclerotic Cardiovascular Disease Risk?
Yeonyee E. Yoon, Bo La Yun, Kyoung Min Kim, Jung-Won Suh